TITLE

Hospital, Drug-Maker Team Up to Test New Error Reporting System

AUTHOR(S)
Page, Douglas
PUB. DATE
May 2009
SOURCE
H&HN: Hospitals & Health Networks;May2009, Vol. 83 Issue 5, p14
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Brigham & Women's Hospital in Boston, Massachusetts and pharmaceutical company Pfizer launched the Adverse Drug Event Spontaneous Triggered Electronic Reporting (ASTER) pilot program. The program was designed to examine if an electronic health record (EHR) can alert the U.S. Food and Drug Administration (FDA) to potential drug side effects. Overview of how EHR under ASTER works is presented.
ACCESSION #
40829083

 

Related Articles

  • FDA field targets ADR submissions. James G., Dickinson // Medical Marketing & Media;Oct97, Vol. 32 Issue 10, p30 

    Reports on the US Food and Drug Administration field compliance program for drug firms with a history of adverse drug reaction reporting problems. Examination of completion and accuracy of ADR submissions; Internet address of the compliance program.

  • Irinotecan-induced severe neutropenia: UGT1A1 variant alleles.  // WHO Drug Information;2010, Vol. 24 Issue 2, p107 

    The article discusses the U.S. Food and Drug Administration's 2005 decision to amend the warning label on the drug irinotecan because of an increase in neutropenia in patients who are homozygous for the enzyme UGT1A1. A discussion of research from several countries that found that the drug led...

  • Lessons from cisapride.  // CMAJ: Canadian Medical Association Journal;5/01/2001, Vol. 164 Issue 9, p1269 

    Editorial. Comments on the warning system in Canada about adverse side effects of drugs. Case of cisapride, a drug prescribed for stomach disorders, which caused fatal cardiac arrhythmias; How Health Canada lagged behind the United States Food and Drug Administration (FDA) in warning...

  • Dalbavancin is expected to have FDA approval soon.  // Drug Formulary Review;May2008, Vol. 24 Issue 5, p39 

    The article reports that hospital pharmacies are expecting the availability of Pfizer Inc.'s potent antibiotic drug Dalbavancin after the U.S. Food and Drug Administration (FDA) sent a drug approval letter in late December 2007. Hospital pharmacies emphasized their willingness to stock the drug...

  • FDA warns Pfizer to report Rx problems promptly.  // Drug Topics;5/20/96, Vol. 140 Issue 10, p8 

    Reports on the US Food and Drug Administration's (FDA) warning letter to Pfizer regarding the company's tardiness in reporting unexpected side effects with its prescription drugs.

  • Pfizer fined. Harrington, John // Crain's New York Business;12/6/93, Vol. 9 Issue 49, p42 

    Reports on the $290,000 fine imposed by the Food and Drug Administration (FDA) on the Manhattan, New York City-based drug manufacturer Pfizer Inc. for marketing a pump that was modified without the FDA approval. Imposition of the fine through the Infusaid Inc. of Pfizer Incorporated.

  • FDA approves Pfizer Viagra drug.  // Chemical Market Reporter;04/06/98, Vol. 253 Issue 14, p19 

    Announces that the Food and Drug Administration has approved the market introduction of the drug Viagra developed by Pfizer Inc. for the treatment of erectile dysfunction effective April 1998. Revenue expectations from sale of drug.

  • FDA warns Pfizer about Zoloft promotions.  // Drug Topics;8/19/96, Vol. 140 Issue 16, p11 

    Relates that the Food & Drug Administration has apprehended Pfizer regarding the distribution and promotion of brochures on anti-depressant drug Zoloft for use as treatment for dysthymia, premenstrual dysphoric disorder and other ailments. Reaction of company to FDA memo to pull out materials...

  • Editors Note. Kubick, Wayne // Applied Clinical Trials;Jan2013, Vol. 22 Issue 1, p8 

    The author focuses on the development of clinical data terminology by the U.S. Food and Drug Administration (FDA) through the Clinical Data Interchange Standards Consortium (CDISC), an open standards development organization under the Prescription Drug User Fee Act (PDUFA V).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics